Thrombolex Inc.

Founded in 2016, Thrombolex, Inc. is engaged in the design, development, manufacture and distribution of innovative endovascular catheters.

09/01/2025

Happy Labor Day from Thrombolex.

Thrombolex.com

08/29/2025

Watch as Dr. Wissam Jaber discusses how the BASHIR™ Endovascular Catheter demonstrates significant clinical improvements in the treatment of acute pulmonary embolism compared to historical data on mechanical thrombectomy, particularly in reducing pulmonary artery obstruction and relieving right heart strain.

Thrombolex.com

08/25/2025

Dr. Wissam Jaber discusses how Thrombolex's new single-session PE protocol streamlines patient throughput by eliminating the need for post-procedural infusion and ICU admission, delivering a more efficient therapeutic approach.

Thrombolex.com

08/21/2025

In this clip, Dr. Barry Bertolet discusses how the BASHIR™ Endovascular Catheter offers greater efficiency in resolving both proximal and distal thrombus compared to large-bore mechanical thrombectomy (LBMT), while enhancing air exchange at the distal subsegmental pulmonary artery level and ultimately contributing to improved patient outcomes.

Thrombolex.com

08/18/2025

Efficient delivery. Better outcomes. Clinical confidence.
The BASHIR™ Endovascular Catheter is a clinically proven, single-session solution for the treatment of acute pulmonary embolism. Its proprietary dual-action design mechanically fissures the thrombus while delivering targeted low-dose thrombolytics. This results in safe, effective, and rapid resolution of both proximal and distal thrombus.

Thrombolex.com

08/12/2025

Watch as Dr. Barry Bertolet discusses how the low-profile BASHIR™ Endovascular Catheter offers a more efficient therapy by enabling smaller venous access and reducing access site complications.

Thrombolex.com

08/08/2025

The RESCUE-II Study, recently published in JACC: Advances, evaluated the safety and feasibility of single-session pharmaco-mechanical lysis (PML) using the BASHIR™ Endovascular Catheter. With no post-procedural infusion required and no major bleeding events, this clinically proven solution represents a safe, targeted approach to treating PE. https://lnkd.in/g9PvMfcj

08/05/2025

Recently published in the Journal of Vascular and Interventional Radiology: Two complex cases of acute portomesenteric thrombosis highlight the use of the BASHIR™ Endovascular Catheters as part of a multicatheter thrombolysis approach via TIPS access. In both cases, multiple BASHIR™ Endovascular Catheters were used in parallel to target extensive thrombus across the portal and splenic veins. This allowed for effective thrombolysis while maintaining hemostasis, showing the Catheter’s versatility in high-risk scenarios.

Learn more here: https://doi.org/10.1016/j.jvir.2025.03.009

Thrombolex.com

07/04/2025

Wishing everyone a safe and happy Fourth of July.

Thrombolex.com

06/30/2025

The BASHIR™ Endovascular Catheter is a clinically proven solution for the safe and effective treatment of pulmonary embolism (PE). Engineered to deliver low-dose, targeted thrombolytics directly to the clot, supporting efficient, on-the-table PE care. Enhancing lytic delivery and eliminating the need for post-procedure ICU infusions, the BASHIR™ Endovascular Catheter helps physicians focus on what matters most: faster recovery and better outcomes.

Thrombolex.com

06/28/2025

PE treatment isn’t just about removing the clot, it’s about what comes next. Thrombolex is focused on what matters most: patient outcomes. The RESCUE-II study shows how the BASHIR™ Endovascular Catheter is designed to effectively treat both proximal and distal thrombus.

No need for ICU Infusion
29.2% Reduction in Pulmonary Artery Obstruction
No Major Adverse Events
0% Major Bleeding Rate

Learn more at Thrombolex.com

06/25/2025

Compelling results from our RESCUE-II Study have been recently published in JACC: Advances. Results demonstrated the safety and feasibility of on-the-table pharmaco-mechanical lysis (PML) using the BASHIR™ Endovascular Catheter for the treatment of acute pulmonary embolism (PE). This Study further validates the role of the BASHIR™ Endovascular Catheter as a clinically proven solution in the treatment of PE. Read the full publication in JACC: Advances: https://www.sciencedirect.com/science/article/pii/S2772963X25002078

https://thrombolex.com/rescue-ii-study-results-published-in-jacc-advances/

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Thrombolex Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in New Britain?